uconn health

Institutional Review Board Meeting Dates and Submission Deadlines

There are two IRB Panels, each scheduled to meet once per month. With the following exception, studies are assigned to a panel based on submission deadlines. Once a study is assigned to an IRB panel, the study remains under that panel’s oversight for the life of the study.

Any study proposing to include prisoners as subjects must be submitted for review by Panel 02. Panel 02 reviews all other types of studies as well as prisoner studies.

Panel Meeting Date Submission Deadline Date Assigned Regulatory Specialist
01 January 8, 2024 December 26, 2023 Stephen MacKinnon
02 January 22, 2024 January 9, 2024 Patty Gneiting
01 February 5, 2024 January 23, 2024 Stephen MacKinnon
02 February 26, 2024 February 13, 2024 Patty Gneiting
01 March 4, 2024 February 20, 2024 Stephen MacKinnon
02 March 18, 2024 March 5, 2024 Patty Gneiting
01 April 1, 2024 March 19, 2024 Stephen MacKinnon
02 April 15, 2024 April 2, 2024 Patty Gneiting
01 May 6, 2024 April 23, 2024 Stephen MacKinnon
02 May 20, 2024 May 7, 2024 Patty Gneiting
01 June 3, 2024 May 21, 2024 Stephen MacKinnon
02 June  17, 2024 June 4, 2024 Patty Gneiting
01 July 8, 2024 June 25, 2024 Stephen MacKinnon
02 July 15, 2024 July 2, 2024 Patty Gneiting
01 August 5, 2024 July 23, 2024 Stephen MacKinnon
02 August 19, 2024 August 6, 2024 Patty Gneiting
01 September 9, 2024 August 27, 2024 Stephen MacKinnon
02 September 16, 2024 September 3, 2024 Patty Gneiting
01 October 7, 2024 September 24, 2024 Stephen MacKinnon
02 October 21, 2024 October 8, 2024 Patty Gneiting
01 November 4, 2024 October 22, 2024 Stephen MacKinnon
02 November 18, 2024 November 5, 2024 Patty Gneiting
01 December 2, 2024 November 19, 2024 Stephen MacKinnon
02 December 16, 2024 December 3, 2024 Patty Gneiting
01 January 6, 2025 December 24, 2024 Stephen MacKinnon
02 January 27, 2025 January 14, 2025 Patty Gneiting
01 February 3, 2025 January 21, 2025 Stephen MacKinnon
02 February 24, 2025 February 11, 2025 Patty Gneiting
01 March 3, 2025 February 18, 2025 Stephen MacKinnon
02 March 17, 2025 March 4, 2025 Patty Gneiting
01 April 7, 2025 March 25, 2025 Stephen MacKinnon
02 April 21, 2025 April 8, 2025 Patty Gneiting
01 May 5, 2025 April 22, 2025 Stephen MacKinnon
02 May 19, 2025 May 6, 2025 Patty Gneiting
01 June 2, 2025 May 20, 2025 Stephen MacKinnon
02 June 16, 2025 June 3, 2025 Patty Gneiting
01 July 7, 2025 June 24, 2025 Stephen MacKinnon
02 July 21, 2025 July 8, 2025 Patty Gneiting
01 August 4, 2025 July 22, 2025 Stephen MacKinnon
02 August 18, 2025 August 5, 2025 Patty Gneiting
01 September 8, 2025 August 26, 2025 Stephen MacKinnon
02 September 15, 2025 September 2, 2025 Patty Gneiting
01 October 6, 2025 September 23, 2025 Stephen MacKinnon
02 October 20, 2025 October 7, 2025 Patty Gneiting
01 November 3, 2025 October 21, 2025 Stephen MacKinnon
02 November 17, 2025 November 4, 2025 Patty Gneiting
01 December 1, 2025 November 18, 2025 Stephen MacKinnon
02 December 15, 2025 December 2, 2025 Patty Gneiting
01 January 5, 2026 December 23, 2025 Stephen MacKinnon
02 January 26, 2026 January 13, 2026 Patty Gneiting
01 February 2, 2026 January 20, 2026 Stephen MacKinnon
02 February 23, 2026 February 10, 2026 Patty Gneiting
01 March 2, 2026 February 17, 2026 Stephen MacKinnon
02 March 16, 2026 March 3, 2026 Patty Gneiting
01 April 6, 2026 March 24, 2026 Stephen MacKinnon
02 April 20, 2026 April 7, 2026 Patty Gneiting
01 May 4, 2026 April 21, 2026 Stephen MacKinnon
02 May 18, 2026 May 5, 2026 Patty Gneiting
01 June 1, 2026 May 19, 2026 Stephen MacKinnon
02 June 15, 2026 June 2, 2026 Patty Gneiting
01 July 6, 2026 June 23, 2026 Stephen MacKinnon
02 July 20, 2026 July 7, 2026 Patty Gneiting
01 August 3, 2026 July 21, 2026 Stephen MacKinnon
02 August 17, 2026 August 4, 2026 Patty Gneiting
01 September 14, 2026 September 1, 2026 Stephen MacKinnon
02 September 21, 2026 September 8, 2026 Patty Gneiting
01 October 5, 2026 September 22, 2026 Stephen MacKinnon
02 October 19, 2026 October 6, 2026 Patty Gneiting
01 November 2, 2026 October 20, 2026 Stephen MacKinnon
02 November 16, 2026 November 3, 2026 Patty Gneiting
01 December 7, 2026 November 24, 2026 Stephen MacKinnon
02 December 21, 2026 December 8, 2026 Patty Gneiting

 

Scientific Review Committee

The Scientific Review Committee (SRC) ensures that the scientific question being asked within a protocol is relevant and that the design of the protocol is appropriate to answer that question. A guide for using iRIS  to access the material to be reviewed is available by clicking the Help button within iRIS.

The SRC review will primarily focus on the elements of good scientific study design. Proposals will be evaluated for the following criteria:

  • clarity of the research question,
  • appropriateness and efficiency of design,
  • rigor and feasibility of methods,
  • qualifications and expertise of the research team,
  • scholarship and pertinence of background material and rationale,
  • adequacy of sample size and relevance of controls,
  • and the validity of the statistical analysis plan.

In addition, the Committee may desire to comment on the proposal’s scientific relevance or compelling ethical or patient safety issues. The SRC will submit a summary of their evaluation to the IRB and report their final recommendation as (1) recommend approval without revision, (2) recommend approval pending acceptable revision, or (3) recommend rejection. Recommendations will be based on consensus. The Scientific Review Committee may call upon a consultant if additional expertise is needed to conduct a review. The opinion of the consultant will be taken into consideration when developing the final report. The fact that a consultant was utilized will be noted in the letter to the IRB.

The IRB requires scientific review for all studies reviewed by the convened board that have not already undergone review by another body. The IRB also reserves the right to send any study to the Scientific Review Committee for evaluation. The Scientific Review Committee will generally meet the week before the scheduled IRB meeting to discuss the research protocol.

A member will not review any protocol in which s/he has an interest in the study. If needed, the IRB may call upon the Scientific Advisory Committee of the General Clinical Research Center for assistance.

Scientific Review Committee Membership:

  • Dr. Julie Wagner, Chair, Professor, Oral Health and Diagnostic Sciences
  • Dr. Sheila Alessi, Associate Professor, Calhoun Cardiology Center
  • Dr. Biree Andemariam, Professor, Neag Comprehensive Cancer Center
  • Dr. Lance Bauer, Professor, Psychiatry
  • Dr. Molly Brewer, Professor, Obstetrics & Gynecology
  • Dr. Kevin Claffey, Professor, Cell Biology
  • Dr. Justin Cotney, Associate Professor, Genetics and Genomic Sciences
  • Dr. Jonathan Covault, Professor, Psychiatry
  • Dr. Richard Fortinsky, Professor, Center on Aging
  • Dr.  Ivo Kalajzic, Professor, Center for Regenerative Medicine and Skeletal Development
  • Dr. Jayesh Kamath, Professor, Psychiatry
  • Dr. Carla Rash, Associate Professor, Calhoun Cardiology
  • Dr. Tannin Schmidt, Associate Professor, Biomedical Engineering

Guidance on the IRB Submission Process

GET HELP: iRIS is the system used to submit materials to the IRB for review.  Individual who need to use iRIS are strongly encouraged to review the iRIS User Guides available within the Help section of iRIS, and/or attend an iRIS training sessions before using  the system for the first time. Contact the HSPP at irb@uchc.edu with questions pertaining to iRIS training or if additional guidance is needed regarding the IRB submission process (e.g. initial submission, continuing review, request for modification, problem report form).

The IRB Regulatory Specialists (Patricia Gneiting x4849, Steve MacKinnon x8729) are also available to provide assistance.

General Tips:

Allow yourself a sufficient amount of time for the IRB approval process to occur. The terms expedited and exempt do not mean a quicker response time from the IRB.

Review the categories of research that may be exempt or that may be reviewed through the expedited process to determine whether your study qualifies for exemption or expedited review.  The PI/study team make the initial assessment, but the IRB will make the final determination.

Select a faculty member to be the Principal Investigator (PI) of the project. Students, residents and fellows cannot be the PI on an IRB application requesting exemption, expedited review or full board review.

If your study does not qualify for expedited review or exempt status, it will be reviewed by a  convened panel of the IRB. Each panel is scheduled to meet once per month.

Use the applicable submission checklist (full boardexpedited or exempt) to make sure you have all required documents for your submission.

If documents will require translation, obtain approval of the English version first, and then submit the translated documents for approval as a request for addendum/modification.

Ensure all study personnel have completed the CITI training as early as possible. Training is good for three years and must be completed prior to IRB approval being granted.

The project should be defined before you begin the process of completing the IRB paperwork. You should have the research question well formulated and know exactly what data you will be collecting and how they will be analyzed.

When possible build flexibility into the protocol to avoid protocol deviations.

  • For example, in a survey study state in the protocol that minor adjustments to surveys may be made in the field to improve clarity or address cultural sensitivities.  Also note that if done the revised survey will be provided to the IRB for reference at the first possible opportunity.  This would allow you, for example, to reorder questions, or break one question into multiple parts, without having to first obtain IRB approval.   (Note substantive content change would require IRB approval first, e.g. inclusion of new questions).
  • For example, in a treatment study, if possible, rather than saying subjects will be seen 30 days after the first appointment, allow for flexibility in the scheduling by say subjects will be seen 30 days (+/- 5 days) after the first appointment.

Make sure there is consistency between the IRB documents. For example the IRB application, HIPAA Authorization, Informed Consent Form and your protocol should all be consistent regarding what procedures will be done, what data will be collected etc.

Do not delay the submission of your project when you are waiting for “static” documents, such as a permission letter to conduct the study off-site or proof of completion of human subjects protection training, because this type of document will not affect the content of your project. Submit all of the other documents and indicate on the electronic IRB submission by comment that you are in the process of obtaining the relevant document(s). In this manner the content of your project can be evaluated concurrently and will help reduce the amount of time required to obtain approval. Note that final approval will not be granted until all required documents have been provided to the IRB.

 Ask questions early on in the process. You can contact the individuals noted above for assistance.

General Review Process:

Expedited and exempt applications are generally screened within 10 days of receipt. If needed, a communication is sent requesting additional information/clarification before the submission is assigned for official review. Once all necessary information and/or documentation has been received the application packet is forwarded for official review. The official review may result in additional questions.

If a new study requires review by a convened panel, it will be assigned to the next panel meeting for which the submission deadline has not passed.   If the study includes prisoners as  subjects it must be reviewed by Panel 2.  After the meeting the Regulatory Specialist will prepare the minutes and give members 48 hours to comment on such.  Within approximately 10 days after the meeting the IRB will issue a letter noting the outcome from the meeting.

You cannot begin the project until you have IRB approval.

General Documents to Submit for Expedited or Exempt Research:

The following information is intended to serve as a general guideline for what documents must be submitted with various study designs that are common to expedited and exempt projects. Because every study is unique it is not possible to provide directions that will address every situation. The documents common to all new submissions are noted in the first row and additional documents that are often associated with specific study designs follow.  Investigators should use the Exempt Submission Checklist or the  Checklist for Expedited Submissions  as the official guide for what documents to provide. In addition the Request for Exemption or Request for Expedited Review Form should completed as noted on the applicable checklist. Some projects may combine characteristics of more than one study type. Items with an asterisk (*) indicate documents that are created by the investigator.

Type of Study Documents to Submit Comments
1.  All Studies The protocol may be provided by a sponsor, but for most expedited/exempt submission the protocol is developed by the study team.  Use of a Protocol template is strongly encouraged. If another protocol format is used the IRB reserves the right to still require completion of this form. Protocol templates are available on the forms page.
2.  Chart Reviews with Identifiers retained Based on the information that will be abstracted from the medical chart, create your own data collection form.
3. Chart Reviews when identifying information  is seen but WILL NOT be recorded The PI must sign the form to create a de-identified data set, most often under option 2. The person(s) abstracting the data from the medical record must also sign the certification of de-identification form.
4. Survey / Interview Studies Subjects of interview/survey studies must be informed of certain elements of consent via either a cover letter or introductory paragraph. Refer to the Sample Cover Letter.  Most survey studies will qualify for exemption.  If not, and the study is reviewed under an expedited category, informed consent must be addressed

If the study involves PHI HIPAA must also be addressed.

Vulnerable Subjects
Inclusion of Children in non-exempt research If the IRB determines the study is above minimal full board review will be required.

The form to obtain permission from parents may be modeled after the Informed Consent Template

UConn Health students/employees as subject population in non-exempt research
  • Relevant Documents from above
  • Form S (Word)
 Applicable only when there is a relationship that may create undue influence and the research seeks to specifically enroll students or employees (e.g. teacher/student or supervisor/employee).   Employees or students who respond to general recruitment material aimed at a broader audience are not considered vulnerable.
Inclusion of Pregnant Women, Neonates in non-exempt research
  • Relevant Documents from above
  • Form B204 (Word) for pregnant women
  • Form B205 (Word) for neonates
Special Situations:
Studies in Foreign locations or off of UConn Health grounds (e.g., in an elementary school setting) Note: If that site has its own Institutional Review Board you may need to obtain IRB approval from that site in addition to UConn Health.
Conflicts of Interest For all studies, the PI (or designee) is responsible for soliciting information as to whether any study personnel have a significant financial interest related to the research.  Proof that this informant was solicited from study personnel should be maintained in the regulatory binder for the study.  The disclosure form, and if applicable corresponding management plane, is only required to be submitted to the IRB if a study team members discloses that s/he does have a significant financial interest.

 

Research Adverse Events

The IRB requires reporting of unexpected adverse events that may represent an unanticipated problem involving risks to subjects or others (UPIRSO). Such events are to be reported using the Problem Report Form within iRIS. Upon review the Institutional Review Board (IRB) may require changes to informed consent forms and/or protocols or other actions such as increased monitoring. The IRB makes the final determination as to whether an internal adverse event constitutes an unanticipated problem. For external events, the sponsor should indicate if they have deemed the event to be a UPIRSO, and if so the IRB is to be informed.  If the sponsor rules that an external event is not a UPIRSO, if the PI disagrees with the assessment of the sponsor the PI can elect to submit a problem report form and explain this difference in opinion.

All investigators and study personnel must be familiar with the policy for reporting unanticipated problems, inclusive of unexpected adverse events that may be unanticipated problems, to the IRB. Such events must be reported using the Problem Report Form within iRIS within five working days of becoming aware of the event.

The following table summarizes the reporting requirements of adverse events that may constitute an unanticipated problem involving risk:

Event Type Internal or External Expected or Unexpected Related or Not Related to Study Time Frame
Serious Internal Unexpected Related or possibly related 7 calendar days, Continuation, Closure
Serious External Unexpected Related or possibly related to the research and specifically deemed by the sponsor to be an unanticipated problem* 7 calendar days, Continuation, Closure

Investigators can provide sponsors with a copy of the HSPP’s policy for reporting unanticipated problems and/or a copy of the letter from the Director of the HSPP that states that only those external events that have been deemed by the sponsor to be unanticipated problems involving risk to subjects or others will be reviewed by the IRB.

 

Information for Investigators

HELP:  Individuals are strongly encouraged to review the iRIS User Guides, and/or attend an iRIS training session before using the iRIS electronic submission system for the first time.  Guides are available by clicking the Help button within iRIS.  After reviewing the material, if you still have questions pertaining to the use of iRIS, contact  the HSPP at irb@uchc.edu.  The IRB Regulatory Specialists (Patricia Gneiting x4849, Stephen MacKinnon x8729) are also available to provide assistance.

The following general information may be helpful to investigators.

 

 

 

Research Compliance Monitoring

The Research Compliance Monitor is charged with auditing IRB approved studies. The purpose of this program is to provide a systematic, internal process that will increase compliance with federal, state and institutional requirements, and also ensure that research is conducted in accordance with the approved protocol and the ethical principles set forth in the Belmont Report. The policy and procedures related to the audit program are set forth in policy 2009-005.0 titled Monitoring of IRB Approved Studies.

All studies, including those determined to qualify for exempt status and those for which IRB oversight has been deferred, are subject to audit. Studies may be randomly selected or selected for other reasons as described in the monitoring policy.

Receiving notification that a study has been selected for a monitoring visit does not imply that there is anything wrong with the conduct of the study.   For studies reviewed by the local IRB, the activities and conduct of the IRB are also monitored in conjunction with each study that is monitored.

Institutional Review Board Instructions, Forms, and Samples

The electronic submission system, iRIS, is available at https://imedris.uchc.edu.  Your UConn Health username and password will grant you access to the system.

GET HELP: Individuals are strongly encouraged to review the iRIS User Guides, and/or attend an iRIS training session before using iRIS  for the first time.  Contact the HSPP at irb@uchc.edu with questions pertaining to iRIS training. The IRB Regulatory Specialists (Patricia Gneiting x4849, Steve MacKinnon x8729) are also available to provide assistance.

All documents submitted to the IRB must be typed. Cells on the forms will expand to accommodate text. If you cannot access the documents, experience a problem with the formatting, or have general questions about preparing a submission to the IRB contact one of the individuals noted above.

For each submission, save the relevant documents to your hard drive and complete them accordingly. Always refer back to this web site  when submitting forms to the IRB to ensure you are using the most recent version of the document. The IRB reserves the right to return outdated forms. A log describing changes that have been made is available at the bottom of the page.

Human Subjects Training

All key personnel associated with a study, including those authorized to obtain consent, must complete human subjects training. Completion of this training will be verified by staff within the IRB.  New investigators and research personnel who have not yet completed training should complete the CITI Basic Course Requirement.  For those whose training is more than 3 years old, a CITI refresher course is available.

Starting the IRB Process

Your research protocol and plans for implementation of it (e.g. recruitment process, consent process) should be well formulated before you begin the process of preparing an IRB application. When UConn Health will be the IRB of Record, the first step is to determine whether your study will require review by the full board or whether it will qualify for expedited review or exempt status. To make this determination first review the categories of research that may qualify for an exemption. If the research does not appear to qualify for exempt status, review the categories of research that may be permitted under expedited review. If the research does not appear to qualify for exempt status or expedited review, full board review will be required and the submission deadlines will apply. Once you have determined the type of review that is required you should use the applicable Checklist from the list below and prepare/provide those documents that are relevant to your study. Use this checklist to communicate with the IRB if you need to convey information about your submission. If items on the checklist do not pertain to your study indicate NA. Once all of your material is complete it is attached to the on-line application in the iRIS system. The IRB staff will then screen the submission and communicate with you regarding any corrections or clarifications that may be needed.

All documents noted below are in Word format unless otherwise noted.

Determining Whether IRB Review is Required

Instructions

Routine UConn Health IRB Forms

UConn Health IRB Templates for Standard Consent/Assent and Requests for Waivers

Vulnerable Population Forms

  • Form B204 – Research Involving Pregnant Women, or Fetuses – (2/22/2022-clarified instructions)
  • Form B205 – Research Involving Neonates -(2/25/2009)
  • Form B206 – Research Involving Placenta or Fetal Material(2/25/2009)
  • Form B207 – Research Involving Pregnant Women, Fetuses or Neonates not Otherwise Approvable (2/25/2009)
  • Form C – Protections for Prisoners – (2/25/2009)
  • Form D– Additional Protections for Children Involved as Subjects in Research (4/3/2017)
  • Form S– Protections for Other Vulnerable Groups –  (12/9/2014)

UConn Health HIPAA Forms

dbGaP Access Request

Sample Documents & Guidelines

Registries/Repositories

Humanitarian Use Device

Adverse Event Documents

Document Change Reference Log
Change Log 3/20/2024

Institutional Review Board (IRB)

There are two Institutional Review Board (IRB) panels constituted at UConn Health. Institutional policy number 2002-42, Review and Approval of Research Involving Human Subjects (PDF), assigns authority and responsibility to the IRBs.  Panels 1 and 2 meet once per month. With the following exception, studies requiring full board review are assigned to a panel based on the submission date of the initial application.

Exception:

  • Any study proposing to involve prisoners must be assigned to Panel 02 which has a prisoner advocate as a member.

Once a study is assigned to a panel it remains under the oversight of that same panel for the life of the study.  The IRB Office is located on the 5th floor of the L Building.

Federal regulations (e.g. 45 CFR 46, 21 CFR 50 and 56) require that the IRB review and approve any non-exempt research involving human participants, or exempt research that requires limited IRB review, prior to it being started and that, in the majority of cases, legally effective informed consent of the subject or the subject’s legally authorized representative is obtained prior to any involvement in the study.  At UConn Health the IRB is also responsible for determining if research meets criteria for exemption.

Vested with an ethical imperative to safeguard the rights and welfare of human subjects in research studies, the IRB reviews protocols to assure that the research activities proposed include no unnecessary risks, minimize potential risks to subjects, and that overall potential benefit to the subject, or to society, is reasonable in relation to the risks. The Board also measures the importance and significance of the scientific knowledge potentially gained against risks to study subjects.

“Risks to subjects are minimized by:

  • using procedures which are consistent with sound research design and which do not unnecessarily expose subjects to risk;
  • and whenever appropriate using procedures already being performed on the subjects for diagnostic or therapeutic purposes.”

The IRB examines and approves all proposed informed consent forms to ensure that subjects are provided with a clear and complete explanation of the study and its potential benefits and risks.  When applicable, the IRB also ensures that additional protections afforded under regulation to children, pregnant women, and prisoners have been addressed.

In general, the membership of IRB meets on the first, and  third working Mondays of each month; applications requiring review by the full IRB are due 12 working days prior to the meeting. Applications requesting exempt status or expedited review may be submitted at any time. Once approved, when continuing review is a requirement protocols must be reviewed at least annually. All studies, including exempt studies, are subject to audit by the Research Compliance Monitor.

Finally, approval for emergency and therapeutic use of investigational new drugs (IND’s) must be obtained from the IRB.

IACUC Contacts

Institutional Animal Care and Use Committee
UConn Health Center
263 Farmington Avenue
Farmington, CT 06030-1523
Phone: 860.679.3429
Fax: 860.679.1005
Email: ooacc@uchc.edu

 

Committee Contacts

Name Title Phone Email
Alison D. Pohl, MS, rLATg, CPIA Research Compliance Monitor II
IACUC Administrator
860.679.4129 pohl@uchc.edu
Lisa A. Chuba, BS, LAT Research Compliance Monitor I 860-679-4726 lchuba@uchc.edu
Stephen Crocker, Ph.D. IACUC Chair 860.679.8750 crocker@uchc.edu
Melissa Caimano, Ph.D. IACUC Vice-Chair 860.679.8390 mcaima@uchc.edu
Ramaswamy Chidambaram, BVSc, MSc, Ph.D. Director, CCM and Attending Veterinarian 860.679.2248 ramaswamy@uchc.edu
Dan Sasso, B.S. Chemical Specialist (working with chemical hazards in animals) 860.679.4062 sasso@uchc.edu

 

Leadership Contacts

Name Title Phone Email
Karen Moré, MS, CPIA Director, Research Compliance and Integrity 860-486-2459 karen.more@uconn.edu
Michael Centola, MHS, CIP AVP, Research Compliance and Integrity 860-679-6568 centola@uchc.edu

OCTR Procedures for the School of Medicine

The purpose of the OCTR is to provide clinical researchers administrative assistance with the following tasks:

  • Contract and clinical trial budget negotiations
  • Fiscal set up and oversight of Banner research accounts including account reconciliation and closeout
  • Development of viable study budgets
  • Identification of studies that qualify for Medicare reimbursement as “qualifying clinical trials”
  • Identification of research subjects and research charges, through quality monitoring and audit, to assure research financial compliance

The Budget Workbook is used to standardize the research budget process. It provides accurate study budget calculations for clinical trials, regardless of the sponsor.

Some Helpful Information

  • Institutional policies supporting OCTR procedures can be found on the Institutional Policies page.
  • Flow charts that provide a visual representation of the procedures are available and each flow chart is followed by a companion narrative description.
  • Acronyms and definitions found within the documents maybe be found on the following pages:
Procedure Title Description
OCTR Process Overview Understanding the Overall Process of the OCTR
Procedure I Flow Sheet Budget Process: Determination Schema Industry Sponsored, Industry Supported, University to University, Co-operative Group or Foundation Supported Clinical Trials
Procedure I Narrative Following Flow Sheet Budget Process: Determination Schema Industry Sponsored, Industry Supported, University to University, Co-operative Group or Foundation Supported Clinical Trials
Procedure I.a Flow Sheet Budget Process: Determination Schema Federal or Awards in Response to a Public Solicitation
Procedure I.a Narrative Following Flow Sheet Budget Process: Determination Schema Federal or Awards in Response to a Public Solicitation
Procedure II Flow Sheet Registering Clinical Trial
Procedure II Narrative Following Flow Sheet Registering Clinical Trial